NET LOSS PER SHARE

9 Months Ended

Sep. 30, 2024

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the three and nine months ended September 30 (in thousands, except for per share amounts):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Loss from continuing operations, net noncontrolling interests and accrued preferred stock dividends	$	(56,117)	$	(578,514)	$	(127,721)	$	(717,946)
Loss from discontinued operations	(14,358)		(67,843)		(42,662)		(240,321)
Net loss attributable to NeueHealth, Inc. common shareholders	$	(70,475)	$	(646,357)	$	(170,383)	$	(958,267)
Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted	8,282		7,977		8,205		7,945
Basic and diluted loss per share attributable to NeueHealth, Inc. common shareholders
Continuing operations	$	(6.78)	$	(72.52)	$	(15.57)	$	(90.36)
Discontinued operations	$	(1.73)	$	(8.51)	$	(5.20)	$	(30.25)
Net loss per share attributable to common stockholders, basic and diluted	$	(8.51)	$	(81.03)	$	(20.77)	$	(120.61)

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share because including them would have had an anti-dilutive effect for the nine months ended September 30 (in thousands):


	Nine Months Ended September 30,
	2024	2023
Redeemable convertible preferred stock (as converted to common stock)	5,307	4,599
Issued and outstanding common stock warrants	2,842	1,381
Stock options to purchase common stock	494	673
Restricted stock units	3,028	1,056
Total	11,671	7,709

If the liability classified share-based award, as described in Note 6. Share-Based Compensation, is settled in shares in lieu of a cash settlement additional, potentially dilutive securities, will be issued. Until the determination is made, the number of outstanding potentially dilutive securities is not determinable or estimable.